Search Results - therapeuticarea+%3e+infectious+disease

500 Results Sort By:
Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity
Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID’s Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA...
Published: 7/16/2026   |   Updated: 7/16/2026   |   Inventor(s): David Margulies, Abir Panda, Ethan Shevach, Kannan Natarajan, Patricia Korty
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought, TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease
Detection of Organomercurial Compound Biosynthesis in Microbial Communities
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities. This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination....
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Benjamin Schwarz, Rachel Caspi, Xiaoyan Xu
Keywords(s):  
Category(s): Application > Diagnostics, Application > Occupational Safety and Health, Application > Research Materials, Application > Software / Apps, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Sequences, TherapeuticArea > Gastroenterology, TherapeuticArea > Infectious Disease
AI Based Workflow for Single Cell Analysis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations. This technology includes SCassist, an innovative...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Rachel Caspi, Vijayaraj Nagarajan
Keywords(s):  
Category(s): Application > Research Materials, Application > Software / Apps, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Gastroenterology, TherapeuticArea > Dental, TherapeuticArea > Dermatology, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Endocrinology, TherapeuticArea > Geriatrics, TherapeuticArea > Hematology, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Metabolic Disease, TherapeuticArea > Nephrology, TherapeuticArea > Neurology, TherapeuticArea > Obstetrics/Neo-Natal, TherapeuticArea > Ophthalmology, TherapeuticArea > Psychiatry/Mental Health, TherapeuticArea > Pulmonology, TherapeuticArea > Radiology, TherapeuticArea > Rare/Neglected Diseases, TherapeuticArea > Reproductive Health, TherapeuticArea > Respiratory, TherapeuticArea > Urology, TherapeuticArea > Veterinary
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...
Published: 5/14/2026   |   Updated: 5/14/2026   |   Inventor(s): Patrick Duffy, Jonathan Renn
Keywords(s):  
Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Summary: Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used...
Published: 5/12/2026   |   Updated: 9/29/2025   |   Inventor(s): Zheng-gang Liu, Swati Choksi, PeiXing Wan, Yeon-Ji Park
Keywords(s):  
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Diagnostics, Application > Therapeutics
Innovative Antibody Conjugation Technology for Therapeutic and Diagnostic Applications
This pioneering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform...
Published: 4/14/2026   |   Updated: 9/22/2025   |   Inventor(s): Parinaz Fathi, Frank Borris, Kaitlyn Sadtler
Keywords(s):  
Category(s): Application, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease
Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. Description of Technology: Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused...
Published: 8/21/2025   |   Updated: 8/21/2025   |   Inventor(s): Scott Norberg, Clint Allen, Zulmarie Franco, Ke Bai
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof
Summary: The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP). Description of Technology: Recurrent...
Published: 10/7/2025   |   Updated: 8/21/2025   |   Inventor(s): Scott Norberg, Clint Allen, Xiaolin Wu
Keywords(s):  
Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, Application > Diagnostics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
C8166-45 Cells
Summary: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth. Description of Technology: ...
Published: 8/21/2025   |   Updated: 8/19/2025   |   Inventor(s): Genoveffa Franchini, Syed Salahuddin, Flossie Wong-Staal, Robert Gallo, Phillip Markham, V Kalyanaraman
Keywords(s):  
Category(s): Application > Research Materials, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Chimeric VLP vaccines to Prevent HTLV-1 Infection
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult...
Published: 11/10/2025   |   Updated: 8/12/2025   |   Inventor(s): Genoveffa Franchini, Sarkis Sarkis, Ramona Moles, Cynthia Masison, Massimiliano Bissa
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
1 2 3 4 5 6 7 8 9 10 ...